Transboundary and Emerging Diseases brings together in one place the latest research on infectious diseases considered to hold the greatest economic threat to animals and humans worldwide.
The journal provides a venue for global research on their diagnosis, prevention and management, and for papers on public health, pathogenesis, epidemiology, statistical modeling, diagnostics, biosecurity issues, genomics, vaccine development and rapid communication of new outbreaks.
Papers should include timely research approaches using state-of-the-art technologies.
The editors encourage papers adopting a science-based approach on socio-economic and environmental factors influencing the management of the bio-security threat posed by these diseases, including risk analysis and disease spread modeling.
Preference will be given to communications focusing on novel science-based approaches to controlling transboundary and emerging diseases.
The following topics are generally considered out-of-scope, but decisions are made on a case-by-case basis (for example, studies on cryptic wildlife populations, and those on potential species extinctions):
Pathogen discovery: a common pathogen newly recognised in a specific country, or a new pathogen or genetic sequence for which there is little context about — or insights regarding — its emergence or spread.
Prevalence estimation surveys and risk factor studies based on survey (rather than longitudinal) methodology, except when such studies are unique.
Surveys of knowledge, attitudes and practices are within scope.
Diagnostic test development if not accompanied by robust sensitivity and specificity estimation from field studies.
Studies focused only on laboratory methods in which relevance to disease emergence and spread is not obvious or can not be inferred (“pure research” type studies).
Narrative literature reviews which do not generate new knowledge.
Systematic and scoping reviews, and meta-analyses are within scope.
Abstracting & Indexing
ScopusGoogle ScholarWeb of ScienceMedlinePubMedEmbase
Detailed Metrics
Total Docs. (latest)
253
Total Docs. (3 years)
1,053
Total Refs.
13,965
Total Citations (3 years)
3,660
Citable Docs. (3 years)
1,033
Citations / Doc. (2 years)
2.50
Ref. / Doc.
55.20
% Female
41.6%
Metrics Visualization
Latest year data vs 3-year cumulative figures
Female: 41.6% |
Male: 58.4%
Citations / Doc. (2yr)2.50
Average
References / Doc.55.20
High refs
Citable / Total Docs (3yr)98.1%
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Frequently Asked Questions
What is the impact factor of Transboundary and Emerging Diseases?
The official Journal Impact Factor (JIF) is published by Clarivate in the Journal Citation Reports (JCR) and is not listed on this page. Based on SCImago data, Transboundary and Emerging Diseases has an SJR of 0.865 and is ranked Q1.
What is the SJR and quartile of Transboundary and Emerging Diseases?
Transboundary and Emerging Diseases has an SJR (SCImago Journal Rank) of 0.865 and its best quartile is Q1.
What is the H-index of Transboundary and Emerging Diseases?
The H-index of Transboundary and Emerging Diseases is 100, meaning 100 of its articles have each been cited at least 100 times.
Is Transboundary and Emerging Diseases indexed in Scopus?
Yes. Transboundary and Emerging Diseases is active in Scopus (Scopus Source List, August 2026).